Last updated: February 14, 2026
Overview of the Drug
NDC 00054-0482 identifies a formulation of Adalimumab, a biologic drug used primarily to treat autoimmune conditions including rheumatoid arthritis, Crohn’s disease, and psoriasis. Manufactured by AbbVie, it falls under the class of TNF-alpha inhibitors. The drug is marketed under the brand name Humira.
Market Environment
1. Market Size and Growth Trends
- The global autoimmune disease treatment market was valued at approximately USD 140 billion in 2022.
- The biologics segment dominates, with adalimumab constituting about 65% of this market.[1]
- Market growth is forecast at 8.2% CAGR from 2023 to 2030, driven by increasing disease prevalence and broader approval spectrum.[2]
2. Competitive Landscape
3. Regulatory and Patent Data
- Original patent for Humira expired in the U.S. in 2023, enabling biosimilar proliferation.
- Biosimilar pricing varies; U.S. prices range from $1,200 to $1,800 per injection (40 mg), significantly lower than pre-biosimilar prices (~$5,000 per injection).
4. Market Dynamics Post-Patent Expiry
- Market share shift from originator to biosimilars expected to be complete by 2025.
- Price erosion for originator drugs predicted to be between 30% and 50% within two years post-biosimilar entry.
- Payers increasingly favor biosimilars, emphasizing cost savings.
Price Projection Model
1. Current Pricing Landscape
| Product |
Approximate Wholesale Acquisition Cost (WAC) |
Price per 40 mg injection |
Market Share (2023) |
| Humira (original) |
USD 5,000 |
USD 5,000 |
~70% in the US |
| Biosimilars (Amgevita, Imraldi, etc.) |
USD 1,200–1,800 |
USD 1,200–1,800 |
~30% in the US |
2. Short-Term (Next 1-2 Years)
- Biosimilar prices are expected to stabilize at 20–25% less than current original prices.
- The original Humira price could decline by approximately 30–50% due to biosimilar competition.
- The average price per injection could decrease to USD 2,500–3,500, depending on the biosimilar's market penetration.
3. Long-Term (3-5 Years)
- Biosimilar market share is projected to reach 80–90%, accelerating price reductions.
- The originator's price could be near USD 2,000–2,500 per injection.
- New formulations or delivery methods might influence the trajectory but are uncertain.
4. Volume and Revenue Impact
| Year |
Estimated Market Volume (million injections) |
Estimated Revenue (USD billion) |
| 2023 |
10.0 |
50.0 (assuming average USD 5,000 per injection) |
| 2025 |
8.0 |
24.0–28.0 (average USD 3,000–3,500 per injection) |
| 2028 |
9.0 |
18.0–22.5 (average USD 2,000–2,500) |
Market Risks and Drivers
- Price erosion driven by biosimilar competition.
- Reimbursement policies shifting favor to biosimilars.
- Global regulatory approvals expanding biosimilar market penetration.
- Innovation pipelines for future biologics may divert attention or produce competing products.
Summary
The entry of biosimilars into the U.S. and international markets sharply reduces prices for adalimumab (NDC 00054-0482). The originator’s price is expected to decline by half within 2 years, with sustained volume growth partially offset by lower per-unit revenue. Long-term projections suggest stabilization of prices at approximately 40–50% below pre-biosimilar levels, with reduced revenues for the original product.
Key Takeaways
- Biosimilar competition has drastically reduced adalimumab prices since patent expiry in 2023.
- Prices are expected to decline further, reaching 50% below original levels within two years.
- Market volume may decline temporarily but is projected to rebound as biosimilar adoption stabilizes.
- Reimbursement practices favor lower-cost biosimilars, influencing pricing strategies.
- Ongoing innovations may affect the long-term market dynamics.
FAQs
1. How soon will biosimilar versions impact the price of adalimumab?
Significant price reductions are already occurring since biosimilars launched in late 2023, with the effect expected to intensify over the next 1–2 years as market share shifts.
2. What factors influence the price trajectory of adalimumab?
Patent expirations, biosimilar market entry, payer reimbursement policies, and regulatory approvals significantly affect pricing.
3. Will the original Humira price stabilize at its current level?
No, patent expiry and biosimilar competition tend to drive the original's price downward over time, with significant reductions expected within two years.
4. Are biosimilar prices uniform across different countries?
No, biosimilar pricing varies based on regional regulations, market competition, and reimbursement policies.
5. How does market volume influence revenue projections post-biosimilar entry?
Volume reductions due to price decreases can offset revenue losses; however, volume growth in some regions may partially compensate for lower per-unit prices.
Citations
[1] Market Research Future, "Global Autoimmune Disease Treatment Market," 2022.
[2] Grand View Research, "Biologics Market Size & Growth," 2023.
